These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 30537008)

  • 1. Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives.
    Safari E; Ghorghanlu S; Ahmadi-Khiavi H; Mehranfar S; Rezaei R; Motallebnezhad M
    J Cell Physiol; 2019 Jul; 234(7):9966-9981. PubMed ID: 30537008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-derived suppressor cells and tumor escape from immune surveillance.
    Umansky V; Blattner C; Fleming V; Hu X; Gebhardt C; Altevogt P; Utikal J
    Semin Immunopathol; 2017 Apr; 39(3):295-305. PubMed ID: 27787613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
    Qu P; Wang LZ; Lin PC
    Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
    Cai J; Cui Y; Yang J; Wang S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
    Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutualistic Effects of the Myeloid-Derived Suppressor Cells and Cancer Stem Cells in the Tumor Microenvironment.
    Tanriover G; Aytac G
    Crit Rev Oncog; 2019; 24(1):61-67. PubMed ID: 31679221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
    Adah D; Hussain M; Qin L; Qin L; Zhang J; Chen X
    Pharmacol Res; 2016 Aug; 110():25-34. PubMed ID: 27157248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis.
    Safarzadeh E; Orangi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2018 Apr; 233(4):3024-3036. PubMed ID: 28661031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
    Kramer ED; Abrams SI
    Front Immunol; 2020; 11():1963. PubMed ID: 32983128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phytochemicals inhibit the immunosuppressive functions of myeloid-derived suppressor cells (MDSC): Impact on cancer and age-related chronic inflammatory disorders.
    Salminen A; Kaarniranta K; Kauppinen A
    Int Immunopharmacol; 2018 Aug; 61():231-240. PubMed ID: 29894862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells-new and exciting players in lung cancer.
    Yang Z; Guo J; Weng L; Tang W; Jin S; Ma W
    J Hematol Oncol; 2020 Jan; 13(1):10. PubMed ID: 32005273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype.
    Sun Y; Han X; Shang C; Wang Y; Xu B; Jiang S; Mo Y; Wang D; Ke Y; Zeng X
    Cell Death Dis; 2022 Jan; 13(1):36. PubMed ID: 35013108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
    Li BH; Garstka MA; Li ZF
    Mol Immunol; 2020 Jan; 117():201-215. PubMed ID: 31835202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
    Chen Z; Yuan R; Hu S; Yuan W; Sun Z
    Front Immunol; 2022; 13():817942. PubMed ID: 35154134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer.
    Ma J; Xu H; Wang S
    J Immunol Res; 2018; 2018():6319649. PubMed ID: 29765990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.